Evidence map›Paper›PMID 39444413›Full record

ArticleJACC. Advances2024

Particulate Matter 2.5 Pollution Impact on Comorbid Cancer and Cardiovascular Disease Mortality in the U.S.

Ashish Kumar, Sumanth Khadke, Sadeer AlKindi, Sanjay Rajagopalan, Khurram Nasir, Dhruv Kazi, Javaria Ahmad, Safi Khan, Aarti Asnani, Daniel Addison and 12 more

Abstract read
In one paragraph

Article in JACC. Advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Ashish KumarDepartment of Internal Medicine, Cleveland Clinic, Akron General, Akron, Ohio, USA.
Sumanth KhadkeDivision of Cardiovascular Medicine, Department of Cardiovascular Medicine, Lahey Hospital & Medical Center, Burlington, Massachusetts, USA.
Sadeer AlKindiDepartment of Cardiovascular Medicine, Houston Methodist Hospital, Houston, Texas, USA.
Sanjay RajagopalanDivision of Cardiovascular Medicine, Harrington Heart and Vascular Institute, University Hospitals and Case Western Reserve University, Cleveland, Ohio, USA.
Khurram NasirDepartment of Cardiovascular Medicine, Houston Methodist Hospital, Houston, Texas, USA.
Dhruv KaziRichard A. and Susan F. Smith Center for Outcomes Research, Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Javaria AhmadDivision of Cardiovascular Medicine, Department of Cardiovascular Medicine, Lahey Hospital & Medical Center, Burlington, Massachusetts, USA.
Safi KhanDepartment of Cardiovascular Medicine, Houston Methodist Hospital, Houston, Texas, USA.
Aarti AsnaniDepartment of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Daniel AddisonDepartment of Cardiovascular Medicine, Ohio State University; Columbus, Ohio, USA.
Diego SadlerDepartment of Cardiovascular Medicine, Cleveland Clinic Florida; Weston, Florida, USA.
Anita DeswalDepartment of Cardiovascular Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ana BaracDepartment of Cardiovascular Medicine, Inova Heart and Vascular Institute, Annandale, Virginia, USA.
Avirup GuhaDepartment of Cardiovascular Medicine, Medical College of Georgia, Augusta, Georgia, USA.
Jennifer LiuDepartment of Cardiovascular Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
Daniel LenihanDepartment of Cardiovascular Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Tomas G NeilanDepartment of Cardiovascular Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Salim HayekDepartment of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Joerg HermannDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Anju NohriaCardio-Oncology Program, Department of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Sourbha S DaniDivision of Cardiovascular Medicine, Department of Cardiovascular Medicine, Lahey Hospital & Medical Center, Burlington, Massachusetts, USA.
Sarju GanatraDivision of Cardiovascular Medicine, Department of Cardiovascular Medicine, Lahey Hospital & Medical Center, Burlington, Massachusetts, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Background: Evidence regarding the effect of long-term exposure to particulate matter (PM) 2.5 and comorbid cancer and cardiovascular disease (CVD) mortality is limited. Objectives: In this study, the author report the association between long-term exposure to PM 2.5 and CVD mortality, cancer mortality and comorbid cancer and CVD mortality in the U.S. population. Methods: The Centers for Disease Control and Prevention (CDC) WONDER (Wide-Ranging Online Data for Epidemiologic Research) multiple-cause-of-death database was used to obtain U.S. county-level mortality and population estimates from 2016 to 2020. Data on average daily density of PM 2.5 were abstracted from the 2018 CDC's National Environmental Public Health Tracking system. Counties were divided into quartiles with Q1 representing counties with least average daily density and Q4 representing counties with maximum average daily density of PM 2.5. Age-adjusted mortality rates were abstracted for each quartile, for the overall population and subgroups of population. Results: The age-adjusted mortality rates for CVD, cancer, and comorbid cancer and CVD mortality were 505.3 (range: 505.0-505.7), 210.7 (range: 210.5-210.9), and 62.0 (range: 61.8-62.1) per 100,000 person-years, respectively. CVD mortality had the highest percentage excess mortality in Q4 compared with Q1, followed by comorbid cancer and CVD. Cancer had the least percentage excess mortality. A disproportionate effect of PM 2.5 exposure was noted on vulnerable and minority groups, based on Social Vulnerability Index and race stratification, respectively. Conclusions: Higher levels of long-term PM 2.5 exposure reported increased CVD mortality, cancer mortality and comorbid cancer and CVD disease mortality, with a pronounced detrimental effect in vulnerable and minority population.

Indexed as

cancercardio-oncologycardiovascular diseasePM 2.5 exposure

Identifiers

PMID39444413
PMCPMC11496976

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.